0 164

Cited 15 times in

Tissue urokinase-type plasminogen activator receptor levels in breast cancer

DC Field Value Language
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author양우익-
dc.contributor.author정현철-
dc.contributor.author라선영-
dc.contributor.author양우익-
dc.contributor.author정현철-
dc.date.accessioned2019-11-11T05:09:49Z-
dc.date.available2019-11-11T05:09:49Z-
dc.date.issued2000-
dc.identifier.issn1107-3756-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/171662-
dc.description.abstractCancer invasion is induced by several proteolytic enzyme systems associated with the destruction of basement membrane and extracellular matrix. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) have been reported as prognostic factors in breast cancer patients and plasminogen activation is regulated by various factors such as uPAR and growth factors. Thus, we examined the tissue levels of urokinase-type plasminogen activator receptor (uPAR) in breast cancer patients. Tissue uPAR levels were measured by ELISA assay in 268 breast cancer patients. The median and mean values of tissue uPAR level in breast cancer were 3.5 ng/mg cytosol protein and 4.8+/-3.6 ng/mg cytosol protein, respectively. Tissue uPAR level was the highest in T1 stage, but there was no statistical significance between the T stages (p>0.05), nor in nodal stage, in the value of uPAR according to progression. And the value of uPAR expression was not associated with estrogen and progesterone receptor status, number of involved node and percent of node involvement. In TNM stage, tissue uPAR levels were higher in patients with stage I-II than in patients with stage III-IV (p=0.027). In univariate analysis, nodal factor (p=0.002) and TNM stage (p=0.0004) were significant. But, multivariate analysis showed that TNM stage was the only significant prognostic factor (p=0.0002). These results suggest that uPAR is mainly associated with initial tumor invasion and other factors might be involved in later stages of cancer progression.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherD.A. Spandidos-
dc.relation.isPartOfInternational Journal of Molecular Medicine-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBreast Neoplasms/metabolism*-
dc.subject.MESHBreast Neoplasms/mortality-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHEnzyme-Linked Immunosorbent Assay/methods-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPlasminogen Activators/metabolism*-
dc.subject.MESHPrognosis-
dc.subject.MESHReceptors, Cell Surface/metabolism*-
dc.subject.MESHReceptors, Urokinase Plasminogen Activator-
dc.subject.MESHSurvival Rate-
dc.titleTissue urokinase-type plasminogen activator receptor levels in breast cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorS J Gong-
dc.contributor.googleauthorS Y Rha-
dc.contributor.googleauthorH C Chung-
dc.contributor.googleauthorN C Yoo-
dc.contributor.googleauthorJ K Roh-
dc.contributor.googleauthorW I Yang-
dc.contributor.googleauthorK S Lee-
dc.contributor.googleauthorJ S Min-
dc.contributor.googleauthorB S Kim-
dc.identifier.doi10.3892/ijmm.6.3.301-
dc.contributor.localIdA01290-
dc.contributor.localIdA01316-
dc.contributor.localIdA01316-
dc.contributor.localIdA02300-
dc.contributor.localIdA02300-
dc.contributor.localIdA03773-
dc.contributor.localIdA03773-
dc.contributor.localIdA01316-
dc.contributor.localIdA01316-
dc.contributor.localIdA02300-
dc.contributor.localIdA02300-
dc.contributor.localIdA03773-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ01132-
dc.identifier.eissn1791-244X-
dc.identifier.pmid10934293-
dc.identifier.urlhttps://www.spandidos-publications.com/ijmm/6/3/301-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.affiliatedAuthor노재경-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor양우익-
dc.contributor.affiliatedAuthor양우익-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor양우익-
dc.contributor.affiliatedAuthor양우익-
dc.contributor.affiliatedAuthor정현철-
dc.contributor.affiliatedAuthor정현철-
dc.citation.volume6-
dc.citation.number3-
dc.citation.startPage301-
dc.citation.endPage305-
dc.identifier.bibliographicCitationInternational Journal of Molecular Medicine, Vol.6(3) : 301-305, 2000-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.